AR064713A1 - Proteina de fusion que se une a transglutaminasas , composiciones que la comprenden , micro- esferas que la comprenden, usos y metodos - Google Patents

Proteina de fusion que se une a transglutaminasas , composiciones que la comprenden , micro- esferas que la comprenden, usos y metodos

Info

Publication number
AR064713A1
AR064713A1 ARP070105988A ARP070105988A AR064713A1 AR 064713 A1 AR064713 A1 AR 064713A1 AR P070105988 A ARP070105988 A AR P070105988A AR P070105988 A ARP070105988 A AR P070105988A AR 064713 A1 AR064713 A1 AR 064713A1
Authority
AR
Argentina
Prior art keywords
understand
fusion protein
transglutaminases
compositions
methods
Prior art date
Application number
ARP070105988A
Other languages
English (en)
Inventor
P Maffia
D Chiappetta
H Chuluyan
R Reiteri
S Gomez
V Garcia
M Costa
N Amiano
D Guerrieri
N Tateosian
Original Assignee
Consejo Nac Invest Cient Tec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nac Invest Cient Tec filed Critical Consejo Nac Invest Cient Tec
Priority to ARP070105988A priority Critical patent/AR064713A1/es
Priority to PCT/IB2008/055409 priority patent/WO2009083880A1/es
Publication of AR064713A1 publication Critical patent/AR064713A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Proteína de fusion que se une a transglutaminasas, composiciones que la comprenden, micro-esferas que la comprenden, usos y métodos. La proteína de fusion podría comprender un dominio que se une a transglutaminasas, por ejemplo el dominio cementoín y un inhibidor de serina proteasas, poe ejemplo el inhibidor secretorio de proteasas leucocitarias (SLPI). Las proteínas de fusion son utiles para elaborar medicamentos para el tratamiento de: por ejemplo, enfermedades autoinmunes, procesos inflamatorios, cáncer, infecciones y la cicatrizacion de heridas.
ARP070105988A 2007-12-28 2007-12-28 Proteina de fusion que se une a transglutaminasas , composiciones que la comprenden , micro- esferas que la comprenden, usos y metodos AR064713A1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ARP070105988A AR064713A1 (es) 2007-12-28 2007-12-28 Proteina de fusion que se une a transglutaminasas , composiciones que la comprenden , micro- esferas que la comprenden, usos y metodos
PCT/IB2008/055409 WO2009083880A1 (es) 2007-12-28 2008-12-18 Transglutaminases binding fusion protein, compositions comprisinh thereof, micro-spheres comprising thereof uses and methods

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP070105988A AR064713A1 (es) 2007-12-28 2007-12-28 Proteina de fusion que se une a transglutaminasas , composiciones que la comprenden , micro- esferas que la comprenden, usos y metodos

Publications (1)

Publication Number Publication Date
AR064713A1 true AR064713A1 (es) 2009-04-22

Family

ID=40473434

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105988A AR064713A1 (es) 2007-12-28 2007-12-28 Proteina de fusion que se une a transglutaminasas , composiciones que la comprenden , micro- esferas que la comprenden, usos y metodos

Country Status (2)

Country Link
AR (1) AR064713A1 (es)
WO (1) WO2009083880A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201003559D0 (en) * 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
EP2726093A4 (en) 2011-06-28 2015-08-19 Inhibrx Llc WAP DOMAIN FUSION POLYPEPTIDES AND METHOD FOR THEIR USE
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
AU2012275287B2 (en) 2011-06-28 2017-10-05 Inhibrx, Inc. Serpin fusion polypeptides and methods of use thereof
CN110152496B (zh) * 2018-01-30 2021-10-15 广州达济医学科技有限公司 一种白细胞过滤膜及其制备方法
WO2023122120A1 (en) * 2021-12-22 2023-06-29 The Regents Of The University Of California Compositionsand methods for wound healing

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101124248A (zh) * 2004-08-11 2008-02-13 特鲁比昂药品公司 结合域融合蛋白

Also Published As

Publication number Publication date
WO2009083880A1 (es) 2009-07-09

Similar Documents

Publication Publication Date Title
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
CL2011000010A1 (es) Anticuerpo monoclonal anti-peptido beta-amiloide; polinucleotido que lo codifica; hibridoma; metodo de produccion; composicion que lo comprende; uso para tratar enfermedades relacionadas con proteinas amiloides; metodo de diagnostico de las mismas; y kit que lo comprende.
EA201490265A1 (ru) Ингибиторы тирозинкиназы брутона
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
AR064713A1 (es) Proteina de fusion que se une a transglutaminasas , composiciones que la comprenden , micro- esferas que la comprenden, usos y metodos
NO20071740L (no) Humaniserte anti-beta7-antagonister og anvendelser derav
CR10530A (es) Anticuerpos anti-dlla4 y metodos que los usan
BR112013017080A2 (pt) Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
EA200970210A1 (ru) Prlr-специфическое антитело и его применения
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
PE20150729A1 (es) 2,3-benzodiazepines
CR20110544A (es) Anticuerpo antagonista específico para el heterodímero de alfa-4-beta-7
CR10237A (es) Anticuerpos contra la il-22 humana y usos para los mismos
DK2074143T3 (da) Ændrede antistoffer
CL2008002952A1 (es) Proteina de union a antigenos que se une a interleucina-23 humana (il-23); composicion farmaceutica que la comprende; y su uso para tratar inflamaciones mediadas por el sistema inmunitario
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
CO6351750A2 (es) Composiciones y métodos para anticuerpos que se dirigen a la proteina de complementos c5
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
CL2007001665A1 (es) Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
AR071242A1 (es) Anticuerpos anti-cd37
PA8794201A1 (es) Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso
CL2011002756A1 (es) Anticuerpo que se enlaza a la proteina del complemento c3b humana o de cinomolgo; composicion farmaceutica, acido nucleico, vector y celula huesped que comprenden dicho anticuerpo; uso para tratar degeneracion macular relacionada con la edad.

Legal Events

Date Code Title Description
FC Refusal